{"id":16171,"date":"2025-01-07T20:20:29","date_gmt":"2025-01-07T13:20:29","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=16171"},"modified":"2025-01-07T20:20:29","modified_gmt":"2025-01-07T13:20:29","slug":"eyebright-medical-receives-nmpa-class-iii-certificate-for-its-phakic-intraocular-lens","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=16171","title":{"rendered":"Eyebright Medical Receives NMPA Class III Certificate for its Phakic Intraocular Lens"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

HONG KONG<\/span><\/span>, Jan. 7, 2025<\/span><\/span> \/PRNewswire\/ — Eyebright Medical Technology (Beijing<\/span>) Co., Ltd. (“Eyebright Medical<\/b>“, the “Company<\/b>“, Stock Code: 688050.SH<\/b>, together with its subsidiaries collectively known as the “Group<\/b>“)\u00a0is proud to announce that our Phakic intraocular lens, “Loong Crystal PR”, has received Class III Medical Devices Certificate from the National Medical Products Administration (“NMPA<\/b>“).<\/p>\n

\n<\/div>\n

The Loong Crystal PR intraocular lens is meticulously designed for the treatment of adult patients, providing effective correction or reduction of myopia ranging from -3.25D to -18.00D. This lens offers a tailored solution for individuals with varying degrees of myopia, ensuring optimal visual outcomes and enhancing patient satisfaction.<\/p>\n

Constructed from an advanced balanced acrylic material, the Loong Crystal PR incorporates a zero spherical aberration design with a large optical zone and a double concave stable arch height structure. Upon implantation, it serves as a refractive element, significantly improving visual acuity while delivering high-quality postoperative results. This innovative design not only boosts optical performance but also elevates the overall visual experience, meeting the high expectations of patients for visual clarity.<\/p>\n

Eyebright Medical prioritizes technology and continuous innovation, aiming to deliver high-quality, safe, and reliable ophthalmic solutions. Through ongoing research and development, the company is dedicated to expanding the domestic ophthalmology landscape and enhancing the recognition of national brands in the industry.<\/p>\n

About Eyebright Medical<\/u><\/b><\/p>\n

Eyebright Medical Technology (Beijing<\/span>) Ltd (“Eyebright Medical<\/b>“; SH Stock Code: 688050<\/b>.SH<\/b>) is a National High-tech Enterprise and state-level technologically advanced ‘little giant’ enterprises, located in Zhongguancun Science and Technology Park, Beijing, China<\/span>.<\/p>\n

The Company is an innovation-driven ophthalmic medical device manufacturer. Its balanced product portfolio spans three major areas of the ophthalmic field: cataract surgery, myopia management, as well as consumer vision care. Anchored by its three core product categories – intraocular lenses, orthokeratology lenses, and soft contact lenses – the company has strategically expanded its product pipeline to cover the full life cycle of eye health solutions. Eyebright Medical is striding into a world-leading medical enterprise on behalf of China’s<\/span> ‘intelligent manufacturing’ power.<\/p>\n

For more information about Eyebright Medical, please visit the official website of the Group: http:\/\/www.ebmedical.com\/en\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

HONG KONG<\/span><\/span>, Jan. 7, 2025<\/span><\/span> \/PRNewswire\/ — Eyebright Medical Technology (Beijing<\/span>) Co., Ltd. (“Eyebright Medical<\/b>“, the “Company<\/b>“, Stock Code: 688050.SH<\/b>, together with its subsidiaries collectively known as the “Group<\/b>“)\u00a0is proud to announce that our Phakic intraocular lens, “Loong Crystal PR”, has received Class III Medical Devices Certificate from the National Medical Products Administration (“NMPA<\/b>“).<\/p>\n

\n<\/div>\n

The Loong Crystal PR intraocular lens is meticulously designed for the treatment of adult patients, providing effective correction or reduction of myopia ranging from -3.25D to -18.00D. This lens offers a tailored solution for individuals with varying degrees of myopia, ensuring optimal visual outcomes and enhancing patient satisfaction.<\/p>\n

Constructed from an advanced balanced acrylic material, the Loong Crystal PR incorporates a zero spherical aberration design with a large optical zone and a double concave stable arch height structure. Upon implantation, it serves as a refractive element, significantly improving visual acuity while delivering high-quality postoperative results. This innovative design not only boosts optical performance but also elevates the overall visual experience, meeting the high expectations of patients for visual clarity.<\/p>\n

Eyebright Medical prioritizes technology and continuous innovation, aiming to deliver high-quality, safe, and reliable ophthalmic solutions. Through ongoing research and development, the company is dedicated to expanding the domestic ophthalmology landscape and enhancing the recognition of national brands in the industry.<\/p>\n

About Eyebright Medical<\/u><\/b><\/p>\n

Eyebright Medical Technology (Beijing<\/span>) Ltd (“Eyebright Medical<\/b>“; SH Stock Code: 688050<\/b>.SH<\/b>) is a National High-tech Enterprise and state-level technologically advanced ‘little giant’ enterprises, located in Zhongguancun Science and Technology Park, Beijing, China<\/span>.<\/p>\n

The Company is an innovation-driven ophthalmic medical device manufacturer. Its balanced product portfolio spans three major areas of the ophthalmic field: cataract surgery, myopia management, as well as consumer vision care. Anchored by its three core product categories – intraocular lenses, orthokeratology lenses, and soft contact lenses – the company has strategically expanded its product pipeline to cover the full life cycle of eye health solutions. Eyebright Medical is striding into a world-leading medical enterprise on behalf of China’s<\/span> ‘intelligent manufacturing’ power.<\/p>\n

For more information about Eyebright Medical, please visit the official website of the Group: http:\/\/www.ebmedical.com\/en\/<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-16171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/16171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16171"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/16171\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}